THE DEAL, AT A GLANCE
From the announcementMironid
01What it doesADVERTISEMENT Why it matters: Mironid is moving into human testing as several rival ADPKD programmes reach Phase 2 or prepare for pivotal development.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Who is involvedBacked by new investor Scottish National Investment Bank, existing backersFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedMironid raised $46M Series B, announced 2026-08-06From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersMironid's $46M Series B is a mid-market Healthcare & Life Sciences financing that supports clinic entry for its kidney drug while ADPKD competitors are advancing through…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Mironid · Financing Record
Explore source-linked visual explanations for Mironid. Unsupported claims are withheld while source review continues.
Record 9866 · Recorded date: 2026-08-06
Explore company records →